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INTRODUCTION
S
everal human diseases are caused by protein misfold-
ing and the accumulation of toxic protein aggregates
in the cytoplasm or extracellular space; these diseases
include Alzheimer’s and Parkinson’s diseases, type II
diabetes and the spongiform encephalopathies such
as Creutzfeldt-Jakob disease. Therefore, understanding the
molecular mechanisms involved in triggering and/or revers-
ing protein aggregation in vivo is essential for elucidating the
relationship between protein aggregation and disease and for
developing effective therapeutic strategies to prevent, slow-
down, or reverse the progression of these diseases. Several
molecular chaperons have been shown to act individually or
in concert with other chaperones to prevent protein misfold-
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ABSTRACT:
The molecular chaperone Hsp104 plays a central role in
the clearance of aggregates after heat shock and the
propagation of yeast prions. Hsp104’s disaggregation
activity and prion propagation have been linked to its
ability to resolubilize or remodel protein aggregates.
However, Hsp104 has also the capacity to catalyze protein
aggregation of some substrates at speciﬁc conditions.
Hence, it is a molecular chaperone with two opposing
activities with respect to protein aggregation. In yeast
models of Huntington’s disease, Hsp104 is required for
the aggregation and toxicity of polyglutamine (polyQ),
but the expression of Hsp104 in cellular and animal
models of Huntington’s and Parkinson’s disease protects
against polyQ and a-synuclein toxicity. Therefore,
elucidating the molecular determinants and mechanisms
underlying the ability of Hsp104 to switch between these
two activities is of critical importance for understanding
its function and could provide insight into novel strategies
aimed at preventing or reversing the formation of toxic
protein aggregation in systemic and neurodegenerative
protein misfolding diseases. Here, we present an overview
of the current molecular models and hypotheses that have
been proposed to explain the role of Hsp104 in
modulating protein aggregation and prion propagation.
The experimental approaches and the evidences presented
so far in relation to these models are examined. Our
primary objective is to offer a critical review that will
inspire the use of novel techniques and the design of new
experiments to proceed towards a qualitative and
quantitative understanding of the molecular mechanisms
underlying the multifunctional properties of Hsp104
in vivo. # 2009 Wiley Periodicals, Inc. Biopolymers
93: 252–276, 2010.
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ing and aggregation, thereby blocking or reversing protein
aggregation and toxicity in vitro and in vivo. However, the
molecular mechanisms by which molecular chaperones
modulate the aggregation, disaggregation, and clearance of
protein aggregates in healthy and diseased states remain the
subject of debate and intense investigation. Among the dif-
ferent classes of molecular chaperones, only the yeast heat
shock protein Hsp104 has been described to both reverse and
catalyze protein aggregation with different functional and
cellular consequences for each activity.
Hsp104 is a member of the Hsp100/ClpB family of
hexameric AAA1-ATPases.1–3 The family of Hsp100/ClpB
proteins comprises bacterial, fungal, and plant Hsp100
ATPases. Hsp100/ClpB chaperones have the ability to bind
and to remodel non-natively folded polypeptides. They are a
member of the class of Clp ATPases which comprise prokary-
otic hexameric protease subunits such as ClpA, ClpX, and
ClpY.4 However, while Hsp100/ClpB proteins are known to
function as protein disaggregases, they do not possess a pro-
tease function. The molecular mechanisms underlying the dis-
aggregase function are complex and not yet fully understood.
Recent studies have demonstrated that Hsp100/ClpB unfolds
proteins by extracting polypeptide chains from aggregates by
processing them by asymmetrical cycles of ATP hydrolysis
through the central channel of the Hsp100/ClpB hexamer.5–8
The current understanding of their molecular and structural
properties suggests that Hsp100/ClpB proteins, with the help
of the Hsp70/40 chaperone system, break down large aggre-
gates and recover proteins from a non-native insoluble or
aggregated state. The spectrum of substrates for these chaper-
ones includes unfolded polypeptides, amorphous aggregates
of various proteins, and protease resistant amyloid structures
(Table I). Protein disaggregation and clearance by Hsp100/
ClpB proteins is crucial for thermotolerance of bacteria and
low eukaryotes under stress conditions, e.g., heat shock,
and protects against protein aggregation and toxicity in
several cellular and animal models of neurodegenerative
diseases.29,32–34,41–43 The elucidation of the structure-function
relationship of Hsp104 presents a unique opportunity for
determining how protein aggregation is modulated and
reversed in nature. Future work could utilize this knowledge to
develop strategies to prevent or treat protein misfolding dis-
eases by preventing or reversing protein aggregation in vivo.
STRUCTURE AND FUNCTION OF Hsp104
Hsp104 Function is Required Under
Stress Conditions
Hsp104 was initially identiﬁed as the most potent factor con-
tributing to induced stress tolerance of yeast.41 Under normal
growth conditions, Hsp104 is not required for yeast viability
but rather plays a role in prion propagation,44,45 and in the dis-
tribution and inheritance of oxidatively damaged proteins.46,47
A genetic HSP104 knockout yeast strain (Dhsp104) does not
show any defects at normal growth temperatures, but a severe
viability defect becomes evident upon exposure to 15–20%
ethanol or upon heat treatment at 378C followed by a heat
shock of 42–508C, i.e., induced heat shock. Under these stress
conditions Dhsp104 or mutant HSP104 yeast strains show a
1000–10,000-fold reduced survival rate when compared to
wild-type HSP104 strains.48,49 Thus, Hsp104 is essential for
yeast survival under stress conditions. Electron micrographs of
Dhsp104 and wild-type HSP104 yeast cells reveal that the aggre-
gation of proteins is reverted within 120 min after a 448C heat
shock in wild-type cells, while mutant cells are unable to clear
aggregates and die.49 Accordingly, Hsp104 was suggested to be
involved in aggregate clearance, thereby promoting the ther-
motolerance of yeast. The protective function of Hsp104 under
stress conditions cannot be attributed to a chaperone function
in the ‘‘classical’’ sense as it is the case for GroEL. GroEL is a
member of the Hsp60 family of ATP-dependent molecular
chaperones, which are known for preventing the aggregation of
proteins by binding to folding intermediates. The structure of
GroEL provides a protected central cavity, the ‘‘Anﬁnsen’s
cage,’’ in which the captured substrate can fold properly and be
released after ATP hydrolysis.50,51 Similar to GroEL, Hsp104
also shows ATP-dependent substrate afﬁnity and has a large
central channel that can accommodate unfolded polypeptides.
However, in contrast to GroEL, Hsp104 does not assist in pro-
tein folding and has a signiﬁcantly reduced capacity to suppress
the aggregation of denatured substrates such as ﬁre ﬂy lucifer-
ase (FFL, see Table I), even at a chaperone to substrate ratio of
20:1, whereas GroEL reduces 90% aggregation of FFL at a
ratio of 1:1.12 The disaggregation activity of Hsp104 also can-
not be explained by a proteolytic degradation mechanism since
Hsp104 has no intrinsic protease function6,49 and no known
protease subunit as the related Clp ATPases ClpX, ClpY, and
ClpA have.4 Nevertheless, the protective function of Hsp104 in
thermotolerance and aggregate clearance has consistently been
shown to depend on active Hsp104 with two functional nucle-
otide binding domains (NBDs). Notably, yeast strains carrying
the HSP104 ATPase point mutations K218T or K620T that
render the NBDs dysfunctional, show almost the same reduced
thermotolerance as hsp104 deletion strains.49,52
Hsp104 Function Requires the Cooperation of Other
Molecular Chaperones
The function of Hsp104 depends genetically on HSP70. A
yeast strain with a deletion of both HSP104 and HSP70 shows
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even less thermotolerance than the corresponding Dhsp104
deletion strain. Second, when HSP104 is deleted, the overex-
pression of Hsp70 only partially restores thermotolerance.
Moreover, HSP104, which is not essential under normal
growth conditions, turned out to be essential when endoge-
nous Hsp70 levels are reduced, indicating that Hsp104 and
Hsp70 are functionally linked.53 In vivo experiments showing
the reactivation of heat-shock-induced aggregates of
recombinant FFL also suggested that Hsp104 has an Hsp70-
dependent disaggregation activity.49 Hsp104 together with
Hsp70 were shown to recover proteins from heat-induced
aggregates and refolds them into their native state. This re-
covery process depends on fully functional Hsp104 and on
the cooperation of the Hsp70/40 chaperone system as shown
by the in vitro reconstitution of the FFL disaggregation
assay.12 Similar observations were made for the correspond-
ing bacterial homologues ClpB and DnaKJE (prokaryotic
Hsp70/40 with the nucleotide exchange factor GrpE).54–56
Accordingly, 1 lM of each chaperone, Hsp104, Hsp40, and
Hsp70, was required for the refolding of 20 nM of urea-dena-
tured FFL to yield 50% of the activity of the native FFL
control within 30–60 min in the presence of ATP. This refold-
ing activity required a cooperatively acting chaperone, since
none of the assay components exhibited this extent of reacti-
vation activity individually.12 Recent studies have provided
evidence that the disaggregation activity of Hsp104 is
enhanced when Hsp70/40 acts upstream of Hsp104, see later.
The physical interaction of Hsp104 with Hsp40 and/or
Table I Substrates of Hsp104
Substrate Related Phenotype Modiﬁcations Type of Assay References
NONAMYLOIDOGENIC MODEL SUBSTRATES
a-Lactalbumin Carboxymethylated, labeled SEC co-elution, anisotropy 7, 9, 10, 11
a-Casein HAP/ClpP degradation assay 6
b-Galactosidase Urea denatured SEC (oligomerization),
enzymatic
12, 13
FFL lysate assay Yeast expressed FFL Enzymatic 13
FFL Urea denatured, heat denatured Enzymatic 12
FFL-fusions Peptide fusion Enzymatic 9
GFP Thermally denatured Fluorimetric 14
GFP-RepA Contains RepA (1-70) tag Fluorimetric 14
La-EYFP YPF with unfolded lactalbumin tag Fluorimetric 7
Polylysine, 15 kDa Binding assays 9, 15, 16
RepA DNA binding by RepA 14
NATURAL AMYLOIDOGENIC SUBSTRATES
Rnq1, yeast [RNQ1] prion
(5 [PIN1])
Dhsp104 is [rnq 2] Yeast in vivo 17, 18
Sup35, yeast [PSI1] prion :Hsp104 cures, Dhsp104 is [psi 2] Yeast in vivo, biophysical
studies
44, 19, 20–22, 11
Ure2, yeast [URE3] prion Dhsp104 is [ure-o] Yeast in vivo, biophysical
studies
23
24
25
EXOGENOUS AMYLOIDOGENIC SUBSTRATES
Amyloid beta, human Alzheimer’s disease In vivo: no enhanced aggreg.
by Hsp104
Yeast in vivo, biophysical
study
26, 27, 11, 28
a-Synuclein, human Parkinson’s disease :Hsp104: neuro protection Rat in vivo, biophysical study 29
HET-S, Pododspora
anserina (Pa)
[Het-S] prion Dhsp104: HET-S aggreg. reduced,
DPahsp104: no curing
Yeast and Pa in vivo 30, 31
Huntingtin, PolyQ,
human
Huntington’s
disease
Dhsp104: no Htt aggreg., :Hsp104:
neuro protection
Yeast in vivo, C. elegans
in vivo, rat, mouse in vivo
32–38
PrP, human CJD, PrPSc prion Hsp104 promotes conversion
into PrPSc
Biophysical studies 11, 39
PrP, mouse ME7 prion No effect Mouse in vivo 40
:Hsp104 corresponds to the effect of Hsp104 overexpression. [RNQ1], [PSI1], and [URE3] are the prion phenotypes caused by the intracellular amyloid
aggregates of the proteins Rnq1, Sup35, and Ure2, respectively; the corresponding soluble protein states and prion-free phenotypes are [rnq2], [psi2], and
[ure-o], respectively.
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Hsp70 to form a multichaperone complex has been proposed
to explain the high efﬁciency of refolding activity by Hsp104.
Indeed, yeast Hsp40 (yeast Ydj1) was found to be associated
with Hsp104, as revealed by pull-down experiments using
yeast lysate and His-tagged Hsp104.12 As Hsp104 exclusively
cooperates with the corresponding eukaryotic Hsp70 but not
with prokaryotic DnaK,12,18,57,58 a speciﬁc interaction or a
formation of a transient multichaperone complex might be
postulated but has not yet been reported.
Small heat shock proteins (sHsps), such as yeast Hsp26,
were also shown to contribute to aggregate clearance by
Hsp104. sHsps generally bind to partially folded proteins and
associate with them in high molecular weight complexes59–61
or coaggregate with the substrates.62 sHsps, such as Hsp26,
were shown to facilitate the disaggregation by Hsp100/ClpB
when they are preincubated with the substrates before aggre-
gate formation.62–64 Likewise, the molecular chaperone set of
Hsp104/70/40 is more efﬁcient in the reactivation of proteins
when it acts on aggregates that are less tightly packed such as
those formed in the presence of sHsps. Beyond the functional
chaperone cooperation between Hsp104 and Hsp70/40, evi-
dence is accumulating that the tetratricopeptide repeat
(TPR) domain-containing Sti1 and Cpr7 interact physically
with Hsp104. Sti1 and Cpr7 are cochaperones that use a TPR
domain for protein interactions with the acidic C-termini of
eukaryotic Hsp90 and/or Hsp70 (VEEVD or MEEVD). The
binding of Sti1 and Cpr7 to Hsp104 is dependent on its
acidic C-terminal extension (IDDDLD), but the functional
consequences of the interaction are not yet clear. Sti1 and/or
Cpr7 might be involved substrate sorting after release from
Hsp104.15,65
Structural Properties of Hsp104
To gain insight into the molecular mechanisms underlying
the functions of Hsp104 and to understand how it modu-
lates, accelerates, or reverses protein aggregation, it is essen-
tial to review the molecular and structural determinants that
govern the structural properties and functions of this molec-
ular machine in vitro and in vivo. The members of the family
of Hsp100/ClpB proteins are ‘‘motorized’’ molecular chaper-
ones that translate the energy from ATP hydrolysis into
mechanical work, i.e., the unfolding of polypeptides. Similar
to other molecular machines (e.g., the proteasome, polymer-
ases, or F0/F1 ATPase), Hsp100/ClpB proteins possess an
elaborate structural organization that enables the enzymes to
fulﬁll their disaggregation function, an energetically unfavor-
able process. Yeast Hsp104 and its bacterial homologue ClpB
are hexameric AAA1-ATPases with two ATPase sites per pro-
tomer, both of which are essential for the chaperone activity.
The two ATPase sites, or AAA-modules, are referred to as
nucleotide binding domain 1 and 2 (NBD1 and NBD2),
respectively (see Figure 1A). NBD1 and NBD2 are structur-
ally related and share a similar, conserved AAA-fold and
sequence motifs (Figure 1B), but they are not identical in
their structure and function. Structural studies have shown
that each type of NBD of Hsp100/ClpB is found in a parallel
arrangement in the hexamer structure, resulting in a stacked
double ring consisting of NBD1 and NBD2,8,66,67 see Figure
1C. The tight allosteric regulation of the ATPase sites of the
Hsp100/ClpB protomer and the intersubunit cross-talk
within the hexamer is thought to allow substrate binding and
drive substrate unfolding while threading it through the cen-
tral pore of the hexamer.
Functional Regulation and Substrate Processing
by NBD1 and NBD2 of Hsp104
Both NBDs of Hsp104 are indispensable for the chaperone
activity. The NBDs contain the highly conserved Walker A
and Walker B sequence motifs for adenine nucleotide bind-
ing and hydrolysis, respectively,68,69 see Figures 1A and 1B.
The Walker A motif, GxxxxGKT (where x 5 any residue), is
responsible for the binding of the nucleotide. The lysine resi-
due coordinates the phosphate group of the nucleotide and
corresponds to the residues K218 and K620 in the NBDs of
Hsp104. A lysine to threonine mutation in the Walker A
motif abolishes nucleotide binding in the affected NBD of
related ATPases.1,70–72 In Hsp104 and ClpB, this type of
mutation was employed to inactivate one ATPase site, to
determine its function, and to characterize the functional
role of the remaining intact NBD.73–78 A mutation of K218
in Hsp104 into threonine (K218T) results in a loss-of-
function phenotype in vivo and a very strong reduction of
the ATPase activity in vitro without altering the oligomeriza-
tion state of the protein, see Table II. The corresponding
mutation in NBD2 (K620T) also generates a loss-of-function
phenotype, but in vitro assays have demonstrated that this
mutant has an oligomerization defect. Under conditions that
stabilize the hexamer, it regains up to 60% of the wild-type
level of ATPase activity with a moderate chaperone
activity.49,75,76,82 Table II shows a summary of all Hsp104
mutations reported to date and their effect on in vivo func-
tion, on in vitro chaperone and ATPase activity, and on the
oligomerization state. Together, these studies demonstrate
that both NBDs are indispensable for the in vivo activity of
Hsp104 but contribute to such activity via different mecha-
nisms. The high kcat of the ATPase of 70 ATP/min per
monomer of wild-type Hsp10488 can be attributed to
NBD1, whereas NBD2 mainly has a nucleotide-dependent
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oligomerization function.75,82 These functional assignments
are based on Walker A-type mutations, which prevent bind-
ing of nucleotide to the affected NBD. However, both
mutants Hsp104K218T and Hsp104K620T show reduced nucleo-
tide binding at one NBD, reﬂecting a nucleotide state that
might not exist in the wild-type enzyme. Interestingly, other
types of mutation that do not affect ATP binding but exclu-
sively affect hydrolysis show a signiﬁcantly different behavior,
see below.7,9,73 The glutamate residue of the Walker B motif
(hhhhDE, where h 5 hydrophobic residue) is involved in the
hydrolysis of ATP. A mutation of this glutamate inhibits ATP
hydrolysis but does not affect ATP binding in related AAA1-
ATPases.70,72,73,89 In Hsp104, the Walker B glutamate corre-
sponds to the residues E285 and E687 in NBD1 and NBD2,
respectively, see Figures 1A, 1B, and Table II. The corre-
sponding E285Q/A mutants show an unexpected high ATP
turnover of more than 300% of the wild-type activity that
can be only accounted for the remaining intact NBD2,7 sug-
gesting that NBD2 contributes to the enzymatic function as
well as to the oligomerization of the protein. Indeed, the
ATPase activity of NBD2 was found to be strictly dependent
on an ATP-bound state of NBD1.7,90 ATP binding to NBD1
also induces a conformational change that promotes binding
of polypeptide substrates.10 Hence, both, activation of ATP
hydrolysis at NBD2 and polypeptide substrate binding are
controlled by the nucleotide state of NBD1 in order to allow
substrate procession. ATP hydrolysis of either one of the two
NBDs triggers polypeptide substrate release.7 The tightly
FIGURE 1 Structural organization of Hsp104. (A) Domain organization and key residues of
Hsp104 as determined by sequence alignment analysis of Hsp100/ClpB proteins; NTD, N-terminal
domain; molecular dynamics (MD), middle domain; CTD, C-terminal domain. (B) Main structural
motifs of each nucleotide binding domain of Hsp104, NBD1 and NBD2. The indicated key resides
of NBD1 and NBD2 in (A) correspond to the depicted motifs in (B). (C) Cryo-EM reconstruction
of the Hsp104N728A-ATPcS hexamer in a side view and (D) in a top view. The domains of one pro-
tomer within the hexamer are colored as follows: NTD in green, NBD1 in pink, MD in yellow, and
NBD2 in blue. The CTD was not resolved in the structure and is missing from the structural model.
The structure ﬁles of the Hsp104 reconstructions were kindly provided by P. Wendler and H. Saibil,
London.8
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Table II Mutants of Hsp104 Identiﬁed in In Vivo Screens or Designed to Dissect the Function of Individual Domains or Motifs
Site Mutant In Vivo Phenotype
In Vitro Chaperone and
ATPase Activity Oligomerization References
NTD DN (Daa1-147,
aa1-152, or aa1-157)
[PSI1], thermo
tolerance1
100% FFL refolding,
DNHsp104TRAP still
binds to substrates
1 9, 67, 79
NTD inv.110-121
(inverted DNA seq.)
Semi-dominant [PSI 2],
thermotolerance loss
80
NTD F130W Thermotolerance1 16
NBD1 D184N [PSI1], insensitive to
GdmCl
81
NBD1 C209Y Semi-dominant [PSI 2],
thermotolerance2
80
NBD1 G212D Dominant [PSI 2],
thermotolerance loss
80
NBD1, Walker A G215V Thermotolerance loss 49
NBD1, Walker A G217V Thermotolerance loss 1–2% ATPase 1 76, 82, 83
G217S
NBD1 / MD G217S/T499I No growth at 258C,
conditional lethal
83
NBD1, Walker A K218T [1] Semi-dominant [PSI 2],
thermotolerance loss
10–20% FFL refolding, no
substrate binding in
ATPcS-bound state,
1–2% ATPase
1 49, 12, 76,
82, 10, 84
NBD1 / NBD2,
Walker A
K218T/K620T [1] Dominant [PSI 2],
thermotolerance loss
No nucleotide binding Defect 44, 75, 84
NBD1 A220T Semi-dominant [PSI 2],
thermotolerance2
80
NBD1, Diaphragm Y257A Y257A: weak [PSI1],
thermotolerance2
\10% FFL refolding 6, 9, 16, 85
Y257W [4] Y257W: thermo
tolerance1
NBD1 G259D Semi-dominant [PSI 2],
thermotolerance2
80
NBD1, Walker B E285Q/A [1] Hsp70 independent
unfolding activity,
300-500% ATPase with
delayed kinetics
7, 9
NBD1 / NBD2,
Walker B,
TRAP or DWB
mutant
E285Q/E687Q
or E285A/E687A [2]
Tight binding to substrate
in presence of ATP or
ATPcS, ATP binding
without hydrolysis
1 9, 10, 47
NBD1 K302N Dominant [PSI 2],
thermotolerance loss
37
NBD1, Sensor1 T317A [1] Semi-dominant [PSI 2],
thermotolerance2
10% ATPase 1 80, 86
NBD1,
Arginine ﬁnger
R334M Thermotolerance2 20–30% ATPase 2/1 67
NBD1 P389L Semi-dominant [PSI 2],
thermotolerance loss
80
MD R419M Thermotolerance2 20–30% ATPase 1 67
MD R444M Thermotolerance2 20–30% ATPase 1 67
MD Y466W Thermotolerance1 16
MD L462R Semi-dominant [PSI 2],
thermotolerance1
80
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Table II (Continued from the previous page.)
Site Mutant In Vivo Phenotype
In Vitro Chaperone and
ATPase Activity Oligomerization References
MD R495M Thermotolerance2 300% ATPase 1 67
MD T499I Thermotolerance2 30% ATPase 83
MD A503V [PIN1], but toxic to
[PSI1], conditional
lethal, no growth at
378C, but
thermotolerance 11
140% ATPase 37, 83
MD A503V/A509D No growth at 378C,
conditional lethal
83
MD Y507W Thermotolerance1 16
MD A509D Semi-dominant [PSI 2],
thermotolerance 2
100% ATPase 37, 83
NBD1 extension L553W Thermotolerance1 16
NBD1 extension P557L Semi-dominant [PSI 2],
but normal
[URE3],[RNQ1],
thermotolerance 1
80
NBD2, Walker A G617V Thermotolerance loss 52
NBD2, Walker A S618T Thermotolerance1 52
NBD2, Walker A G619V 10–30% ATPase Defecta 76, 82
NBD2, Walker A K620T [1, 3] Semi-dominant [PSI 2],
thermotolerance loss
(K620R:
thermotolerance 1)
30–50% FFL refolding,
binds to substrate in
ATPcS-bound state,
10–60% ATPasea
Defecta 10, 13, 49,
52, 75, 76,
82, 84
NBD2, Walker A T621A 10% ATPase 1 76
NBD2 E645K [psi 2], thermo
tolerance loss
20% FFL refolding, 100%
ATPase
1 85
NBD2 G661D Dominant [PSI 2],
thermotolerance loss
80
NBD2,
Diaphragm
Y662F Y662F: weak [PSI1],
thermotolerance 2
Y662F: 100% FFL
refolding, 107% ATPase
1 6, 8, 9, 85, 79
Y662W [4] Y662W:weak [PSI1],
thermotolerance 2
Y662W: 85% FFL
refolding, 160% ATPase
Y662A Y662A: [psi 2],
thermotolerance loss
Y662A: 0% FFL refolding,
100% ATPase
Y662K Y662K: [psi 2],
thermotolerance loss
Y662K: 0% FFL refolding,
105% ATPase
NBD2, Walker B E687Q/A [1] Hsp70 independent
unfolding activity in
presence of ATP, 75-
100% ATPase
7,9
NBD2 D704N Semi-dominant [PSI 2],
thermotolerance 1
80
NBD2 I722T Thermotolerance1 80% FFL refolding, 300%
ATPase
1 13
NBD2, Sensor1 N728A [1] Semi-dominant [PSI 2],
thermotolerance 22
25% ATPase 1 8, 67, 86
NBD2,
HAP mutant
G739I/
S740G/K741F [5]
[PSI1], thermo
tolerance1
100% FFL refolding 5, 6, 47
NBD2, Arginine
ﬁnger
R765M [3] Thermotolerance2 100% ATPase with
delayed kinetics
Nucleotide
independent
oligomer
67
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regulated interplay between NBD1 and NBD2 appears to
provide the structural basis of the directed translocation of
polypeptides through the central cavity form the N-terminal
to the C-terminal exist site of the Hsp104 hexamer. In the
case of the double Walker B mutant E285Q/E687Q
(Hsp104TRAP, see Table II), no ATP hydrolysis takes place at
all and substrate release is very slow resulting in a highly sta-
ble Hsp104TRAP-ATP-substrate complex.7,10,91 This mutant
has been used as a tool to generate tight binding in several
polypeptide substrate interaction studies.9,10,47,91–93
Additional conserved structural motifs in the nucleotide
binding domains, such as the Sensor 1 motif94 and the
Sensor 2 motif (see Figures 1A and 1B),1 are in close proxim-
ity to the bound nucleotide. Their mutation in Hsp104
leads to an impaired nucleotide hydrolysis or nucleotide
binding, respectively, see Hsp104T317A, Hsp104N728A, and
Hsp104R826M in Table II.86,87 The Sensor 1 mutants
T317A and N278A show nucleotide binding, but no ATP
hydrolysis,86 and have been used as tools to dissect the NBD
functions. Unlike the Walker B mutants, the Sensor 1
mutants exhibit a reduced ATPase activity, suggesting a sec-
ondary functional defect, and they are not reported to from
stable substrate complexes. Nevertheless, the Sensor 1 mutant
Hsp104N728A has been used in cryo-electron microscopy
(Cryo-EM) studies to stabilize the ATP-bound state in
NBD2,8,67 see Figures 1C, 1D, and 2B.
Another important motif within each NBD is the
Diaphragm loop, which is a highly ﬂexible axial channel loop
containing a tyrosine residue. Mutation of the tyrosine residue
of the Diaphragm loop in NBD1 and NBD2 affects the protein
disaggregation activity, see Hsp104Y257A and Hsp104Y662A in
Table II.9,85 This tyrosine is thought to extend into the central
channel of the hexamer, where it may interact with other
Diaphragm loops from the neighboring protomers, according
to the structural model of the related ClpA ATPase,95 and
models of ClpB96 and Hsp104.8 It might restrict the size of the
Table II (Continued from the previous page.)
Site Mutant In Vivo Phenotype
In Vitro Chaperone and
ATPase Activity Oligomerization References
NBD2 F772S [psi 2], thermo
tolerance loss
65% FFL refolding,
150% ATPase
Defect 13
NBD2 K774E Weak [PSI1],
thermotolerance loss
90% FFL refolding,
60% ATPase
Defect 13
NBD2 L814S [PSI1], thermo
tolerance loss
75% FFL refolding,
80% ATPase
Mild defect 13
NBD2 Y819W [4] Thermotolerance1 130% ATPase 1 85–87, 16
NBD2,
Sensor 2
R826M [psi 2], thermo
tolerance2
45% ATPase 1 87
NBD2 L840Q [PSI1], thermo
tolerance loss
110% FFL refolding,
90% ATPase
Mild defect 13
CTD L892W Thermotolerance1 16
CTD D38 (Daa871–908) Weak [PSI1],
thermotolerance loss
\0.1% ATPase Defect 15
CTD D22 (Daa887-908) [PSI1], thermo
tolerance2/1
1.5% ATPase Mild defect 15
CTD D4 (Daa905-908),
putative TPR
interaction site
[PSI1], thermo
tolerance1
80% ATPase 1 15
(1) refers to wild-type-like, (1 1) to enhanced, (2) to reduced, and (2 2) to strongly reduced phenotype or trait. [PSI1] refers to a normal, wild-type
like Sup35 prion propagation, ‘‘weak [PSI1]’’ to a mild suppression of the prion phenotype, [psi 2] to no prion propagation (such as Dhsp104 deletion phe-
notype), and [PSI 2] to an inhibition of prion propagation even if Hsp104WT is present. Dominant or semi-dominant [PSI 2] applies to the effect of the mu-
tant such as Hsp104K218T/K620T expressed in a wild-type background, the effect is most probably due to the formation of nonfunctional hetero-oligomers
which depends for some mutants also on the type of yeast strain. This effect might be true for more mutants but it is hardly tested. The FFL refolding and
ATPase values were roughly estimated based on published work and are given as percentage relative to the given wild-type activity. Several mutants are serving
as specialized tools in functional studies: see [1], mutant serves to dissect NBD functions; [2], serves as trap for substrate binding assays; [3], for oligomeriza-
tion dependency studies; [4], tryptophan ﬂuorescence sensitive to nucleotide binding; and [5], provides new interaction site for ClpP protease and can serve
as substrate trap when combined with inactive ClpP.
a The ATPase of this mutant dependents on oligomeric state but hexamer only present at low salt (20 mM salt), or at a protein concentration
[100 lg/mL.
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central channel of Hsp100/ClpB and/or directly interact with
polypeptide substrates. It has been suggested that
the Diaphragm couples ATP hydrolysis to polypeptide
procession though the channel of the hexamer.5,85,92,97
Therefore, an ATP hydrolysis event in one subunit might be
directly transmitted through movements of the Diaphragm,
mediating the translocation of a polypeptide substrate, see
model in Figure 3B. Together, these ﬁndings suggest that the
structure of the NBDs provides a high level of molecular-me-
chanical regulation of Hsp104. The nucleotide is bound in a
strategic position within each nucleotide binding domain and
between adjacent subunits within the hexamer. Furthermore, a
direct contact of core strands of the ATPase site to the poly-
peptide substrate in the central channel is very likely. This
structural arrangement explains how the energy provided by
ATP hydrolysis can be directly translated into conformational
changes of the domains that drive the translocation of poly-
peptide substrates.
N-Terminal, Middle-, and C-Terminal
Domain of Hsp104
The N-terminal domain, the middle domain, and the
C-terminal domain, see Figures 1A and 1C, also play
important roles in regulating the functional properties of
Hsp104. These domains are involved in mediating
substrate binding and/or speciﬁcity, in transmitting allosteric
communication regarding ATP hydrolysis and substrate
translocation, in the stabilization of the hexamer, or provid-
ing cofactor binding sites.
The N-terminal domain [amino acids (aa) 1–163] is
thought to mediate the initial polypeptide substrate binding,
as has been reported for ClpB from E. coli.92,96,98 Although a
deletion of the entire domain, see Hsp104DN in Table II, does
not have any effect on the in vitro disaggregation activity,
in vivo thermotolerance, and prion propagation by
Hsp104,9,79 mutation of only a short stretch of amino acids
in this domain (Hsp104inv. 110–121) leads to a loss of prion
propagation and thermotolerance,80 see Table II. The func-
tion of the N-terminal domain is not well understood but it
is conceivable that it serves to limit the access to the inner
cavity in order to prevent nonspeciﬁc binding of polypep-
tides. Furthermore, it might be speciﬁcally required for the
binding of prion protein substrates, since Hsp104DN appears
to be defective in the loss of the [PSI1] prion phenotype
upon overexpression.79 In contrast, overexpression of wild-
type Hsp104 leads a loss of the [PSI1] prion state, a phenom-
enon called prion curing.44 Accordingly, the deﬁciency in
prion curing might arise via a partially reduced interaction
of Hsp104DN with prion proteins in the absence of the
N-terminal domain.
The middle domain (aa 412–532, Figure 1A) was origi-
nally assigned as a linker between NBD1 and NBD24; how-
ever, based on sequence alignment analysis and structural
studies, it is now considered an extension of the C-terminal
end of NBD1.66 As mutations within this domain result
mostly in a loss of disaggregation activity for both ClpB and
Hsp104, it was suggested to play a crucial role in the chaper-
one activity. The Cryo-EM reconstruction of the ClpB
hexamer revealed that the middle domain forms a large
coiled-coil stretch at the outer ring surface of the hexamer
with similar appearance to that of propeller blades,66 sup-
porting a central function in the ‘‘crowbar model’’ of poly-
peptide disaggregation.78,96,99–101 However, in the Cyro-EM
reconstitution of Hsp104, this coiled-coil structure appears
to be integrated between NBD1 and NBD2, as well as
between the arrangement of NBDs from neighboring proto-
mers,8,67 see Figure 1C. It has been suggested that this do-
main offers potential binding sites for protein substrates in
the wall of the inner cavity; there it could also provide inter-
action sites for residues involved in nucleotide coordination
and hydrolysis.67,102 Despite the apparent differences between
Hsp104 and ClpB, their structures both suggest that the mid-
dle domain plays a role in translating the ATP hydrolysis
within NBD1 into mechanical energy and movements of the
central cavity and NBD2. The sequence of the middle do-
main is not highly conserved; however, mutagenesis studies
support its relevance for the ATPase and chaperone activity
of Hsp104. Conditional lethal mutants or gain-of-function
mutants, such as G217S/T499I, A503V, or A503V/A509D,
were isolated from in vivo screens. These mutations are
located in the middle domain, see Table II. The mutants show
an altered thermotolerance and/or prion propagation pheno-
type.83 Furthermore, the Hsp104R495M mutant shows an irregu-
larly high ATPase activity.67 Therefore, the middle domain
appears to have a delicate function in the regulation of both the
ATPase activity and the chaperone function of Hsp104.
The C-terminal domain (aa 871–908) ﬂanking the NBD2
of Hsp104 has also been proposed to be involved in substrate
binding.16 However, related Clp ATPases that are associated
with protease cofactors eject substrates at the C-terminal site
in order to feed it to their protease subunit.103,104 Recent
work with the BAP mutant of ClpB and the HAP mutant of
Hsp104, see Table II, in combination with the ClpP protease,
indicated that Hsp100/ClpB proteins also use this domain as
an ‘‘exit’’ site for the translocated substrates.5,6 Furthermore,
the C-terminal domain of Hsp104 plays a role in nucleotide-
independent oligomerization. A deletion of more than 22
residues from the C-terminus of Hsp104 impairs its hexame-
rization.15 In addition, it was shown that cofactor binding
occurs at the extreme C-terminus of Hsp104 (aa 903–908),
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an acidic C-terminal extension (IDDDLD) that is not present
in ClpB and bears some similarity to the C-terminal cofactor
binding motifs of eukaryotic Hsp90 and Hsp70 (VEEVD and
MEEVD).15,52,65,105 Hsp90 and Hsp70 interact with the TPR
domain containing proteins via this stretch of residues.106,107
It is conceivable that the C-terminus of Hsp104 contains a
TPR protein binding motif, possibly linking Hsp104 to the
Hsp70/90 chaperone network of TPR proteins, that might
serve in substrate trafﬁcking.
The Oligomerization State of Hsp104
The oligomeric state of Hsp104 has been investigated exten-
sively using several biophysical and biochemical techniques
including transmission electron microscopy (TEM), analyti-
cal ultracentrifugation, and glutaraldehyde cross-linking
experiments.10,75,76,88 These studies have consistently shown
that Hsp104 exists predominantly as a hexamer. The ﬁrst
glimpse of the structure of the Hsp104 hexamer was pro-
vided by negative staining TEM studies of recombinant
Hsp104 puriﬁed from yeast lysate that revealed ring-like par-
ticles with 6-fold symmetry in the presence of ATP,75 see also
current TEM image in Figure 2A. Recent structural studies
employing Cryo-EM techniques combined with crystallo-
graphic methods conﬁrmed these ﬁndings, showing a hex-
americ protein complex with a central channel.8,66,67 The
hexameric complex of Hsp104 has an outer dimension of
around 160 A˚, revealing a strong structural plasticity with
nucleotide-induced conformational changes, and a large
FIGURE 2 Oligomerization of Hsp104. (A) Current TEM image showing oligomeric Hsp104-ATP
complexes at a concentration of 500 lg/mL; oligomer: see example at arrow; bar: 20 nm. (B) Side
views of Cryo-EM reconstructions of Hsp104N728A showing different hexamer conformations
depending on the type of bound nucleotide. The structure ﬁles of the Hsp104 reconstructions were
kindly provided by P. Wendler and H. Saibil, London.8 (C) The oligomerization equilibrium of
Hsp104 is dependent on several factors, i.e., high protein concentration, binding of nucleotide, or low
ionic strength stabilize the hexamer. The monomer is depicted in light grey, the apo-hexamer in grey,
and the ATP-bound hexamer in blue. (D) Glutaraldehyde cross-linking of Hsp104WT and
Hsp104K620T showing the hexamer formation dependent on the protein concentration and the pres-
ence of ATP, over an Hsp104 concentration range from 5.1 to 510 lg/mL (50–5000 nMmonomer) af-
ter cross-linking. Samples were cross-linked in physiological buffer containing 150 mM KCl and
10 mM MgCl2. A total of 80 ng protein was loaded in each lane of the SDS-PAGE gel and subjected
to electrophoresis followed by silver staining; only the hexamer band is depicted.
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central cavity whose inner diameter changes from 28 to 78 A˚,
depending on whether the protein is in an ADP, ATP-bound,
or ATPcS-bound state (ATPcS is an ATP analogue, which can
be slowly hydrolyzed by NBD1 but is not hydrolyzed by
NBD2.7), respectively,8,67 see also Figures 1C, 1D, and 2B.
These emerging structures provide important insight into
the structural basis of the disaggregation activity and the do-
main movements in the ATPase cycle of hexameric
Hsp104.8,66,67,96 The current structural model of Hsp104 also
reveals signiﬁcant domain movements upon ATP binding
and hydrolysis. The movements of the N-terminal domain
and NBD1, in particular, lead to the displacement of putative
substrate binding sites, thus providing structural basis for
substrate threading from the N- to the C-terminal site of the
Hsp104 hexamer. Interestingly, the reconstitution of the hex-
americ structure in complex with ATPcS yields arrangements
with a marked asymmetry. This suggests that the nucleotide-
bound state of Hsp104 probably exists as a mixed ATP/ADP
complex and/or that ATP hydrolysis by the hexamer takes
place in a nonconcerted fashion,8 possibly in order to allow a
step-by-step translocation of polypeptide substrates through
the central pore.
Hsp104 Oligomerization: Concentration, Nucleotide,
and Ionic Strength Dependence
The oligomerization of Hsp104 exhibits concentration,
ionic strength, and nucleotide dependence,75,76,86 see
Figure 2C. Cross-linking experiments showed that the wild-
type protein is mostly hexameric at protein concentrations of
100 lg/mL (1 lM monomer concentration). At lower
protein concentrations, \100 lg/mL, Hsp104 exists in
an equilibrium of hexamers and monomers, with the mono-
mer being the predominant species at concentrations of
\10 lg/mL, see Figure 2D. The oligomerization of
Hsp104 is also driven by its binding to ATP, which
stabilizes the hexamer. Hence, the majority of structure
determination studies were carried out in the presence of
ATP or its nonhydrolyzable or slowly hydrolyzable
analogue ATPcS. In the absence of nucleotide, the hexamer
is less stable, but can still form at a higher protein concen-
tration of 500 lg/mL (5 lM monomer concentration),
see Figure 2D. The ATPase mutant Hsp104K620T has a nucle-
otide binding defect in NBD2 and shows reduced
hexamer formation even in the presence of nucleotide.75
However, only the hexameric state of Hsp104 is enzymati-
cally active. A direct relationship between hexamer
formation and ATPase activity is supported by site-directed
mutagenesis, concentration-dependent, and salt-dependent
oligomerization studies.76,82,86 Accordingly, several Hsp104
mutants, e.g., Hsp104K620T, Hsp104G619V, Hsp104F772S,
Hsp104K774E, and C-terminal truncation mutants such as
Hsp104D38, exhibit a reduced hexamer formation and con-
comitantly a reduced ATPase and/or chaperone activ-
ity.13,15,76 This reduction in activity can be recovered under
conditions that promote hexamerization, i.e., high protein
concentration (100 lg/mL) or low salt conditions.13,76
The salt dependency of the oligomerization was demon-
strated by static light scattering experiments in the absence
of ATP. At around 20 lg/mL, Hsp104WT forms a 600 kDa
complex in 20 mM NaCl, consistent with the hexamer
as the predominant species. However, in the presence of
200–300 mM NaCl, the monomer becomes the predomi-
nant species in solution.86 Accordingly, by carefully ﬁne-
tuning the ionic strength and the protein concentration,
the hexamer can be stabilized in the absence of nucleotides
or disassembled in the presence of nucleotides.82,86,88
However, several Hsp104 mutants, e.g., Hsp104K218T,
Hsp104T317A, Hsp104T621A, and Hsp104N728A, are ATPase
deﬁcient, despite their wild-type ability to form a hex-
amer.10,75,76,82 Taken together, these ﬁndings demonstrate
that the hexamer formation is necessary but not sufﬁcient
for Hsp104 ATPase and chaperone activity.
Hsp104 Oligomerization In Vivo
It is noteworthy that all structural and oligomerization stud-
ies described earlier exclusively employed in vitro techniques.
Direct evidence of the existence of Hsp104 hexamers in vivo
is still lacking. However, mutagenesis and functional studies
consistently point to the hexamer as the primary functional
species of Hsp100/ClpB in vivo. Mutants that are defective
in oligomerization, such as Hsp104K620T, Hsp104F772S,
Hsp104K774E, and Hsp104D38 (see Table II), are unable to
fully complement HSP104 deletions in yeast.12,13,49,82 On the
other hand, the oligomerization dynamics are required for
Hsp104 function in vivo, since Hsp104R765M, a hexamer sta-
bilizing mutation, is deﬁcient in yeast thermotolerance. In
vitro experiments revealed that the R765M mutation stabil-
izes the Hsp104 hexamer and renders it insensitive towards
nucleotide-induced oligomerization, although it retains up
to 100% of wild-type ATPase activity,67 see Table II. This
mutation alters the putative Arginine Finger in NBD2
(see ‘‘R’’ in Figure 1B), a structural motif important for the
allosteric regulation of related AAA1-ATPases,108 that might
have an allosteric function beyond the stabilization of the
hexamer. Indirect conﬁrmation of the oligomerization of
Hsp104 in vivo is derived from studies aimed at understand-
ing the role of Hsp104 in prion propagation using Hsp104
point mutations. In these studies, the coexpression of wild-
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FIGURE 3 Models of the disaggregation activity of Hsp104. (A) Crowbar mechanism of Hsp104.
The Hsp104 hexamer is presented in a side view. The aggregate is bound at several sites on the outer
surface of Hsp104 and, by cycles of ATP hydrolysis along with signiﬁcant conformational move-
ments, Hsp104 induces partial unfolding or loosening of the bound aggregate. This mechanism was
proposed to mediate mechanical fragmentation of large aggregates, e.g., aggregate loosening. (B)
Substrate threading mechanism of Hsp104. Cross-sections of Hsp104 are depicted in three ATPase
cycles. ATP binding and hydrolysis by Hsp104 drives conformational movements and the substrate
binding cycle. First, substrates transiently interact with Hsp104WT in the ATP-bound state. This
early substrate interaction might be supported by Hsp70/40 targeting the substrates for disaggrega-
tion. During the ATPase cycle, possibly in the ATP transition state, a high afﬁnity state tightly binds
the substrate to the Diaphragm loops in the central cavity of Hsp104, and Hsp104 undergoes strong
conformational changes that cause a structural distortion of the bound substrate. The following
ADP state has low substrate afﬁnity and allows substrate release or it might allow transient relaxa-
tion of the substrate within the central channel. However, the ATP, ADP, and apo-states might be
mixed within one hexamer and the role of each subunit upon translocation still needs to be investi-
gated. Based on the available biophysical data it can be speculated that, by several sequential cycles
of ATP hydrolysis, the substrate is dragged into the cavity and becomes translocated. The number
of ATPase cycles may depend on the folding stability of the substrate or on the degree of aggrega-
tion. After release at the C-terminal site of Hsp104 the substrate is initially unfolded and might be
subjected to the chaperone activity by Hsp70/40 to reach the native state and/or be handed over to
TPR proteins for further substrate targeting.
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type Hsp104 with the Walker A double mutant
Hsp104K218T/K620T results in an elimination of the prion phe-
notype,44,84 and a loss of thermotolerance and protein disag-
gregation activity.109,110 This mutant has a dominant nega-
tive effect on the Hsp104-related functions when expressed
in a wild-type background. Thus, the mutant generates the
phenotype of an HSP104 deletion even if wild-type Hsp104
is present in the cells.44,84,109–112 Based on these in vivo
observations, it was concluded that the inactivation of wild-
type Hsp104 was due to the formation of mixed hetero-
oligomers with the mutant. A close examination of the litera-
ture reveals that several further mutations can be classiﬁed as
semi-dominant, i.e., they partly suppress wild-type Hsp104
activity. For example, the coexpression of the single point
mutants Hsp104K218T and Hsp104K620T leads to a reduced
thermotolerance and suppresses the [PSI1] prion phenotype
but does not cure it, as the double mutant Hsp104K218T/K620T
does.44,76,84 The effect of these semi-dominant mutants on
[PSI1] prion propagation by Hsp104WT also depends on the
genetic background, i.e., the yeast strain,44 and the dosage of
mutant protein.76,109 In vitro data support the hypothesis
that hetero-oligomerization causes a loss of function, i.e.,
that one or two defective subunits within the hexamer are
sufﬁcient to ‘‘poison’’ the activity of the hexamer.76,93
Accordingly, the incorporation of a substoichiometric
amount of an inactive mutant into wild-type Hsp104 hexam-
ers results in a signiﬁcant reduction of the ATP turnover and
chaperone activity in vitro, as well as impaired thermotoler-
ance and prion propagation in vivo.
Taken together, the formation of putative mixed oligo-
mers in vivo as well as the negatively stained images of hexame-
ric Hsp104 protein puriﬁed from yeast75 provide strong
circumstantial evidence for the formation of the Hsp104 hex-
amer, but very little is known about the dynamics and cellu-
lar determinants of Hsp104 oligomerization in vivo. Hsp104
has a basal expression under physiological growth conditions
and is upregulated under stress conditions. Its physiological
level under nonstress conditions was estimated to be about
33,000 molecules per haploid yeast cell grown at 308C.113
This number of molecules corresponds to a minimal cellular
concentration of 0.8 lM monomeric Hsp104 (82 lg/mL),
assuming a cell volume of about 7 picoliters.114 However,
Hsp104 is a protein that is found in the cytosol and in the
nucleus115 and that occupies only a fraction of the total cell
volume. Accordingly, it can be assumed that the physiological
Hsp104 concentration is higher than 100 lg/mL, which
would be sufﬁcient to stabilize the hexamer, see Figure 2D.
Interestingly, the addition of molecular crowding agents has
been shown to restore the ATPase activity of oligomerization
deﬁcient mutants in vitro.15 However, in vitro data on the
oligomerization might not be applicable to in vivo condi-
tions because unknown factors including protein–protein or
protein–small molecule interactions could also inﬂuence the
oligomerization of Hsp104 in vivo. Beyond the physiological
conditions, yeast exhibits the highest stress resistance when
cells are preconditioned by mild nonlethal stress that triggers
increased expression of Hsp104 6–8-fold.116 Thus, endoge-
nous Hsp104 levels are strongly increased resulting in
enhanced concentration-dependent oligomer formation
under conditions where the survival of the yeast cell is
dependent on a fully functional Hsp104. Importantly, the
promoter of Hsp104 contains several stress-inducible cis act-
ing elements including 5 HSE, 6 STRE elements and other
transcription factor binding sites that play a role in drug and
metal resistance. Therefore, the overexpression of Hsp104 is
likely to be induced not only after heat shock induction but
also by a wide range of other stress factors.117–120
Hsp104-MEDIATED DISAGGREGATION
The Crowbar Disaggregation Model
Several models have been proposed for Hsp104-mediated
disassembly and clearance of protein aggregates. Initially,
it was suggested that Hsp100/ClpB functions as a molecu-
lar crowbar on stable aggregates,12,56,66,121,122 see Figure
3A. In the crowbar model, Hsp104 is thought to function
by disrupting large aggregates into smaller particles,
whereby the misfolded proteins become more accessible
for the refolding performed by the Hsp70/40 chaperone
system. This model has recently been supported by the
Cryo-EM structure of ClpB; the middle domain of ClpB
is found in the outer equatorial region of the hexamer
structure.66,99 The movement of this domain is thought to
act as a propeller blade that mediates the splitting of large
aggregates into smaller ones.66 This domain, although not
conserved, is sensitive to mutations. Several mutations in
the middle domain perturb the in vivo chaperone func-
tion of Hsp104, see Table II.16,67,83 The crowbar model
assigns a highly important role to the middle domain and
explains the minor role of the N-terminal domain in
chaperone activity; the N-terminal domain is dispensable
for chaperone function in vivo and in vitro.9,67,79 How-
ever, recent structural studies on Hsp104 locate the mid-
dle domain as coiled-coil integrated into to the arrange-
ment of NBD1 and NBD2, not on the outer surface of
the hexamer,8,67 see Figures 1C and 1D. It is noteworthy,
that in all disaggregation assays, direct evidence for an
aggregate fragmentation activity by Hsp100/ClpB before
refolding by Hsp70/40, or accumulation of fragmented
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aggregates in the absence of functional Hsp70/Hsp40 is
still lacking.
The Substrate Threading Model
An alternative model to explain the disaggregation activity
is the ‘‘threading mechanism,’’ in which Hsp100/ClpB
binds to exposed polypeptide chains or loops of polypep-
tides on the surface of aggregates and threads them
thought the central channel of the hexamer.5,66,85,96,121,122
The central pore in the available structures of Hsp104 or
ClpB is too narrow to allow the translocation of folded
proteins, but is sufﬁciently large (15 A˚) to allow the
translocation of denatured polypeptide chains and poly-
peptide loops, suggesting that protein substrates must
unfold before or during translocation,8,66,67 see Figures 1C
and 1D. In the threading model, the disaggregation activ-
ity of the set of Hsp104/70/40 can be dissected into three
different main stages, see Figure 3B. Figure 3B, upper
panel: (i) Hsp70/40 binds to unfolded or non-natively
polypeptide segments exposed on the surface of aggregates
and presents those substrates to Hsp104. Hsp104 itself
also recognizes unfolded polypeptides, but efﬁcient chap-
erone activity by Hsp104 requires the presence Hsp70/40.
Figure 3B, middle panel: (ii) Once the polypeptide sub-
strate is bound to Hsp104, it starts to be translocated
though the central pore of the hexamer. This process
relies on the highly regulated allosteric interplay between
NBD1 and NBD2, resulting in an unfolding event that
eliminates non-native intermolecular and intramolecular
contacts of the polypeptide to the aggregate. The mecha-
nistic details of the allosteric interplay of NBD1 and
NBD2 upon substrate translocation are yet not clear, but
a tight substrate binding mediated by the Diaphragm
loops of the axial channel might be required for stepwise
translocation via several cycles of ATP hydrolysis by the
hexamer, for detail see (1), (2), and (3) in Figure 3B. Fig-
ure 3B, bottom panel: (iii) The unfolded substrate is
released at the C-terminal site of Hsp104 and, if required,
captured and refolded by Hsp70/40 or transferred to
cochaperones such as Sti1 or Cpr7 for subsequent target-
ing to other chaperones. Therefore, Hsp70/40 may play a
role in substrate targeting also downstream of the Hsp104
translocation for assisting the folding of released unfolded
proteins, possibly depending on the type of substrate.
Several lines of evidences support the threading model:
(i) alanine mutations within the Diaphragm loops of
NBD1 and NBD2 (Hsp104Y257A and Hsp104Y662A in Table
II), which are located in the central cavity of the Hsp100/
ClpB hexamer, show reduced or impaired substrate pro-
tein refolding.5,6,85,97 (ii) Using tryptophan single point
mutants of the Hsp104 Diaphragms, Hsp104Y257W and
Hsp104Y662W, it was possible to demonstrate that the
binding of an unfolded polypeptide causes a ﬂuorescence
quenching of the tryptophan located in the axial channel
indicating that these residues are involved in the binding
of substrate proteins to the central cavity of Hsp104.9 (iii)
As the Diaphragm loop of NBD2 of ClpB can be speciﬁ-
cally cross-linked to denatured FFL only in the presence
of the Hsp70 system, the ﬁndings strongly suggests that
Hsp70/40 play a major role in substrate transfer towards
Hsp100/ClpB.5 (iv) RepA- or lactalbumin-tagged native
green ﬂuorescent protein (GFP) is being unfolded upon
incubation with Hsp104 or ClpB. It has been suggested
that the RepA or lactalbumin tag is recognized, and the
attached GFP is then subsequently unfolded by threading
through the central pore of Hsp100/ClpB.7,14 The crowbar
model does not explain the complete unfolding of native
GFP. (v) The strongest evidence for substrate translocation
was provided by studies on the BAP and HAP mutants of
ClpB and Hsp104, respectively, each containing an IGF
motif insertion that provides a docking site for the ClpP
protease, see HAP in Table II. The engineered mutant
forms a complex with ClpP that is observable by TEM.5
This complex is analogous to the ClpA/ClpP protease
complex, in which the ClpP protease is coordinated at the
C-terminal exit site of the central channel of the ClpA
ATPase hexamer where polypeptide substrates become
ejected.123,124 The ClpBBAP/ClpP or Hsp104HAP/ClpP com-
plex is active in polypeptide degradation but requires the
Hsp70/40 chaperone system. Furthermore, the ClpBBAP/
Hsp70/40 or Hsp104HAP/Hsp70/40 chaperone set is active
in protein refolding when ClpP is absent.5,6 Furthermore,
the addition of an inactive ClpP mutant strongly inhibits
protein disaggregation by ClpBBAP/Hsp70, indicating the
formation of a ClpBBAP/ClpPinactive complex that is pro-
teolytically inactive and blocks disaggregation.5 In addi-
tion, the combination of Hsp104HAP with a ClpPTrap
mutant locks Hsp104 in a substrate-bound state, presum-
ably by impairing substrate release.6
The Intrinsic Unfolding Function of Hsp104
Recent studies have succeeded in demonstrating that
Hsp100/ClpB possesses an intrinsic protein remodeling func-
tion that can be observed independently of the Hsp70/40
chaperone system.7,14 As aforementioned, Hsp100/ClpB has
been shown to actively unfold proteins carrying a denatured
tag, such as fusion proteins containing unfolded a-lactalbu-
min and natively folded GFP. The unfolding of tagged GFP
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can only be observed with wild-type Hsp100/ClpB under
special nucleotide conditions such as the presence of the
slowly hydrolysable ATPcS or the presence of ATP when the
Walker B single mutants Hsp104E285Q or Hsp104E687Q are
used.7,14 Interestingly, by selecting a speciﬁc ATP:ATPcS
ratio, even reactivation of substrates such as RepA or heat
aggregated GFP can be detected in the absence of Hsp70/40.14
The intrinsic unfolding or disaggregation function by Hsp100/
ClpB is experimentally easier to detect, when ATP hydrolysis is
slowed down and/or when one of the two types of nucleotide
binding domain is locked in the ATP-bound state by mutation.
The addition of Hsp70/40 results only in a relatively small
enhancement of substrate disaggregation,14 possibly because
Hsp100/ClpB is the rate-limiting factor under these speciﬁc
conditions. However, the question remains why it is not possi-
ble to observe the intrinsic unfolding function of wild-type
Hsp104 under native assay conditions. Interestingly, the Hsp104
ATPase is strongly activated by the presence of a polypeptide
substrate.7,9,16,26 The observation of an alteration in the ATP
turnover under steady-state ATPase assay conditions supports
the existence of a transient substrate interaction of the wild-
type chaperone. Hence, an explanation for the lack of experi-
mental evidence for the unfolding and translocation under
native assay conditions by Hsp104WT alone might be that poly-
peptide substrate binding is highly transient due to fast on- and
off-rates while ATP is actively hydrolyzed. Substrates might not
be captured for a sufﬁcient time span to allow a complete trans-
location by Hsp104WT alone under physiological steady-state
conditions.
Hsp104 ACTIVITY ON AMYLOID PROTEINS
Principal Characteristics of Yeast Prions
Yeast prions are non-Mendelian genetic elements125 that are
inherited from mother to daughter cells by mechanisms
involving ‘‘protein only’’. Like mammalian prions, they are
dominant phenotypic traits that are self-propagating and in-
fectious. Prions are transmitted upon cell division, by mating
between yeast strains or by experimental protein transfec-
tion,126–129 see Figure 4C. The most prominent yeast prions
are [PSI1], [URE3], and [RNQ1], which are generated by
cytosolic, amyloidogenic aggregates of the proteins Sup35,
Ure2, and Rnq1, respectively.126,130,131 However, more prion
protein candidates exist in yeast.132 Yeast prion proteins are
listed in Table I and do not share sequence homology or
phenotypic characteristics but have in common the propen-
sity to misfold and to form amyloid-like aggregates, the
propagation of which is dependent on the activity of
Hsp104.133,17,23,44 Both overproduction and inactivation of
Hsp104 cause a loss of the [PSI1] prion state, i.e., prion cur-
ing.44 However, even high levels of Hsp104 do not cure the
[RNQ1] and [URE3] prion state.23,133 Thus, the effect of
Hsp104 is dependent on the Hsp104 dosage and on the type
of prion protein. Prion propagation also involves the Hsp70/
40 system134 but is strictly dependent only on Hsp104. The
strength of the prion phenotype, e.g., strong [PSI1] versus
weak [PSI1], depends on the number of prion particles per
cell, which is directly related to the stability of the prion
conformation and the activity or expression level of
Hsp104.135,136 Furthermore, all yeast prions have in common
that the addition of guanidinium hydrochloride (GdmCl) to
the yeast medium leads to prion curing. GdmCl, used in
appropriate amounts, has been shown to act as a speciﬁc in-
hibitor and not as chaotropic agent, causing an inactivation
of Hsp104. Accordingly, not only prion propagation, but also
thermotolerance, and in vitro chaperone activity, are affected
by GdmCl.12,110,137 It has been shown that trace amounts,
such as 500 nM GdmCl, act in vitro as uncompetitive inhibi-
tor of Hsp104, reducing KM and kcat to the same extent, by
altering the allosteric regulation of the ATPase of Hsp104.88
These results demonstrate that small molecules such as
GdmCl can affect the delicate allosteric regulation of the
ATPase machinery of Hsp104, resulting in a loss of both, the
chaperone function and the prion propagation function.
Thus, both functions rely on a fully functional allosteric reg-
ulation of Hsp104.
Models of Prion Propagation: Conformational
Alteration Versus Prion Splitting by Hsp104
While the role of Hsp104 in prion propagation and inheri-
tance is meanwhile established, the exact molecular mecha-
nisms, structural basis, and cellular determinants underlying
this function remain poorly understood. Prion propagation
by Hsp104 has been attributed to its role in the maintenance
of amyloid protein aggregates in the yeast cytosol, thus facili-
tating their passage from mother to daughter cell during cell
division, see Figure 4C. The prion propagation function
seems to contradict Hsp104’s protective role in thermotoler-
ance, where Hsp104 resolublizes amorphous protein aggre-
gates formed under stress conditions, e.g., heat-shock-
induced aggregates, see Figure 4A. However, unlike heat-
shock-induced amorphous aggregates, prion aggregates cor-
respond to amyloid-like structures. The pathway of amyloid
formation is a self-templating polymerization reaction which
results in large, highly stable b-sheet-rich ﬁbrils, see
Figure 4B. Accordingly, prion propagation needs to be exam-
ined in the context of amyloid formation. Two different
models have been proposed to explain the mechanism by
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which Hsp104 mediates prion propagation in yeast.84,109,138
Both models are based on the amyloid formation pathway
and on the ability of Hsp104 to remodel and/or to induce
breakage of preformed protein aggregates, i.e., the disaggre-
gase activity.
The ﬁrst model hypothesizes that Hsp104 induces a con-
formational alteration of the native state of a prion protein
and catalyzes the formation of an intermediate aggregation
competent state, see Figure 5A. The molecular basis of this
effect is not clear, but Hsp104 might act on the native mono-
meric prion/amyloid protein and alter its structure by tem-
porarily unfolding it via translocation through the hexamer.
However, Hsp104 might also offer a speciﬁc binding site for
the amyloidogenic conformation of the monomer and, thus,
stabilize this species by altering the equilibrium with the
native monomer on the pathway of amyloid formation.
From a kinetic point of view, Hsp104 has been suggested to
reduce the barrier of free energy for the transition form the
native to an amyloidogenic intermediate folding state, see1 in
Figure 6. Once formed, these folding intermediates can either
be captured in pre-existing prion aggregates in [PRION1]
cells or revert back into the native state in the absence of
prion particles, such as in [prion2] cells. Thus, Hsp104 may
catalyze the aggregation by promoting the formation of an
aggregation-prone amyloidogenic intermediate.44,84 This
model describes the growth in size of prion aggregates as a
function of Hsp104 but it does not explain how the number
of prion particles is ampliﬁed. It has been suggested that
prion particles might break into smaller pieces naturally
upon growth once they exceed a certain length.84 However, it
became evident that the limiting step in prion propagation
or in prion loss of yeast is determined by the number of
prion aggregates per cell rather than by their size or growth
rate.135,140 Moreover, recombinant yeast prion proteins do
FIGURE 4 Mechanism of nonspeciﬁc aggregation, amyloid formation, and prion propagation.
(A) Nonspeciﬁc aggregation upon heat-induced conformational destabilization: various proteins
are destabilized and undergo unspeciﬁc, non-native interactions resulting in their aggregation and
precipitation. (B) Model of amyloid formation. Amyloidogenic proteins, such as prion proteins,
form highly ordered b-sheet-rich ﬁbrils via oligomeric/protoﬁbrilar intermediates. Once oligomers
have been formed, monomers are continuously added leading to the formation of stable, ﬁbrillar
structures. (C) Prion propagation in yeast depends on the activity of Hsp104 producing prion
propagons by mechanical splitting. The prion seeds or propagons are inherited to the next genera-
tion through cytoplasmatic transduction, i.e., cytoduction.
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FIGURE 5 Mechanism of Hsp104 in amyloid formation. (A) The conformational alteration hy-
pothesis consists of the interaction of Hsp104 with native protein, leading to structural alterations
that prime the formation of prion/amyloid structures. This type of interaction requires ATP and
low concentrations of active Hsp104. (B) Mechanical ﬁbril splitting activity of Hsp104. Hsp104
actively produces amyloid seeds or prion propagons out of mature ﬁbrils. By increasing the number
of seeds, amyloid formation is accelerated. This type of interaction requires ATP and high concen-
trations of active Hsp104. (C) Analogous to (B), Hsp104 may attack prion/amyloid ﬁbrils by the
end, leading, after several cycles of binding, translocation, and monomer release, to a complete dis-
sociation of the ﬁbril. Complete dissociation only occurs if the on-rate of amyloid formation is
lower than the dissociation rate by Hsp104 or if released monomers are removed from the amyloid
formation reaction by attaining their native, nonamyloid folding state. (D) Suppression of amyloid
formation by Hsp104 blocking several species on the pathway of amyloid formation. Hsp104 inhib-
its amyloid formation by sequestering the templating and/or seeding amyloid species from the
pathway and/or by protecting monomers from aggregation. Hsp104 is depicted in gray since the
nucleotide state or ATPase activity does not to seem to be relevant for this type of interaction.
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not require Hsp104 to aggregate or become incorporated in
pre-existing prion particles or amyloid ﬁbrils in vitro.141–143
The prion splitting model suggests that Hsp104 partially
disaggregates [PRION1] complexes into smaller aggregates,
thus, increasing the number of prion particles, i.e., seeds or
propagons. These particles are transferred to daughter cells,
where they can nucleate further aggregation, ensuring the
propagation of prion aggregates from one generation to
another,84,109,138 see Figures 4C and 5B. Consequently, in this
model Hsp104 converts amyloid structures into self-propa-
gating prions. The prion splitting activity suggests that
Hsp104 attacks amyloid ﬁbrils in the middle of the structures
and pulls out single subunits by binding and actively translo-
cating the unstructured polypeptide segments decorating the
surface of amyloid ﬁbrils in an ATP-dependent process, as
indicated in Figure 5B. However, in principle, Hsp104 could
also attack the prion structures at the ends of the amyloid
ﬁbrils, see Figure 5C, where the b-sheet core structures are
accessible. The latter activity would only result in ﬁbril disso-
ciation and not in ﬁbril splitting, i.e., there would be no seed-
ing of amyloid formation. This function would certainly not
maintain a prion phenotype in yeast. It is plausible that both
prion/amyloid ﬁbril splitting and prion/amyloid ﬁbril disso-
ciation take place in parallel, but only the prion splitting
function generates propagons to maintain of the prion state.
Accordingly, the maintenance of prions in yeast can be
explained by a fast on-rate of amyloid formation, i.e., the
growth of prion aggregates, which is, due to the high number
of prion seeds, faster than the dissociation rate achieved by
Hsp104. Several lines of evidence support this hypothesis: (i)
Hsp104 function has been shown to be required for the gen-
eration of propagons but not for the conversion of soluble
proteins into prion complexes.109,112,144,145 (ii) Overexpres-
sion of Hsp104 in yeast partially solubilizes Sup35 aggre-
gates.138 (iii) A reduction of Hsp104 in vivo levels by down-
regulation results in the formation of larger prion aggre-
gates.109 (iv) Time-lapse microscopy of yeast cells shows that
Hsp104 is involved in the remodeling of prion aggregates;
existing Sup35-GFP prion aggregates are dynamic structures
in wild-type yeast cells but become immobile upon Hsp104
inhibition.111 (v) The ability of Hsp104 to propagate prions
is dependent on the stability of the prion aggregates; i.e.,
highly stable prion particles are resistant to fragmentation by
Hsp104 and are inefﬁciently propagated. For example, amy-
loid ﬁbrils generated in vitro at 48C are not very stable and
not tightly packed; however, after in vivo transfection, they
are easily propagated by Hsp104, resulting in a strong [PSI1]
phenotype. In contrast, amyloid ﬁbrils generated at 378C are
more stable and tightly packed, and are more resistant
towards Hsp104-mediated fragmentation and replication,
resulting in a weak [PSI1] phenotype.135,136 Hence, the prion
phenotype directly correlates with the stability of the corre-
sponding amyloid ﬁbrils, affecting the replication efﬁciency
by Hsp104. (vi) In vitro, Hsp104 has been shown to break
down amyloid ﬁbrils of Sup35 and Ure2 into smaller frag-
ments that have the capacity of seeding amyloid formation in
vitro and inducing a prion state by in vivo transfection.19,24
Interestingly, long incubation with Hsp104 has been shown
to give rise to different types of products; the Hsp104 reac-
tion products of Ure2 ﬁbrils are highly efﬁcient in seeding
and propagation of the [URE3] prion irrespective of the
Hsp104 concentration, but Sup35 ﬁbrils are inactivated by
excess Hsp104, and the end product of the reaction does not
efﬁciently function as an amyloid seed or as [PSI1] prion.24
Accordingly, Sup35/[PSI1] prion particles might be more
sensitive to excess Hsp104 than Ure2/[URE3] prion particles.
This might explain the observed differences in prion curing
of [PSI1] and [URE3] upon Hsp104 overexpression in vivo.
(vii) Finally, the addition of GdmCl inhibits Hsp104 and
thus blocks the generation of prion propagons in vivo, with-
out affecting the ability of existing prion aggregates to grow
larger via recruitment of soluble prion protein. However,
these aggregates are diluted out in the growing yeast culture
by asymmetric cell divisions while the mother cells retain the
prion aggregate.111,146 These effects of GdmCl on prion
maintenance were recently used to determine the number of
[PSI1] propagons which was shown to be 300–1300 per yeast
cell, depending on the [RNQ1] state of the cell.140
In conclusion, Hsp104 might exert several activities on
prion proteins and their aggregates in vivo, but the prion
splitting activity dominates other effects so that only the
resulting prion propagation function is apparent. Hsp104-
mediated fragmentation of prion/amyloid aggregates appears
to correspond to an incomplete disaggregation reaction, as
indicated in Figures 3B and proposed in Figures 5B and 5C.
By utilizing a chimeric Hsp104/ClpB construct with the mu-
tant ClpPTrap, which is an analogous experimental setup to
the work on HAP/ClpTrap that provided evidence for the
translocation of substrates by Hsp104,6 Tipton et al. have
shown that prion propagation in yeast is accompanied by the
binding of prion proteins to the chimeric HAP/ClpTrap com-
plex (The combination of the HAP mutant with ClpTrap
serves to trap substrates in a locked translocation-complex
with Hsp104.6). As this was only observed with the [PSI1]
state but not with the [psi2] state, the presented data
strongly suggest that prion protein translocation through the
Hsp104 hexamer is taking place only in yeast cells containing
prion particles being subjected to prion propagation. Inter-
estingly, this complex formation of chimeric HAP/ClpTrap
and prion protein also requires Hsp40 (yeast Sis1) acting
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upstream of Hsp104, which appears to play a role in prion
particle transfer towards Hsp104.18 Accordingly, the prion
propagation function is most likely caused by a substrate
threading reaction of Hsp104 resulting in a splitting of prion
particles into seeds. However, the splitting model for prion
propagation proposes that Hsp104 interacts with ﬂexible
ends of subunits in the middle of the ﬁbril and, upon extrac-
tion of this single subunit, the ﬁbrils break into smaller frag-
ments. One way to rationalize this model is that Hsp104
interacts preferentially with extended cross-b-sheet structures
found, for example, on the surface of amyloid ﬁbrils. How-
ever, the extreme stability of amyloid ﬁbrils in comparison
with nonspeciﬁc aggregates, such as those formed as a result
of heat- or chemical-induced aggregation, argues against this
model. The amyloid ﬁbril represents one of the most stable
structure on the protein level and exhibits strong resistance
towards denaturation or disassociation by proteases, acids,
and chemical denaturants. If the ability of Hsp104 to gener-
ate ﬁbril fragments was dependent on its ability to interact
with exposed loops of the ﬁbril subunits, then Hsp104
should neither exhibit any disaggregation activity nor pro-
mote prion propagation of amyloid forming proteins lacking
exposed termini or partially folded structures in the ﬁbrillar
state. This hypothesis could be tested using amyloid ﬁbrils
lacking exposed ends or partially exposed structures or loops
as substrates. Several small peptides have been shown to
form cross-b amyloid ﬁbrils of diameters equal to the length
of the peptide and thus could be used to test this model.147
FIGURE 6 Hsp104 interacts with several species on the pathway of amyloid formation and aggre-
gation. Hsp104, whose interaction sites indicated in red, can enhance amyloid formation by
(1) mediating the transition from a native to an amyloid structure by the conformational alteration
hypothesis, and by (2) generating amyloid seeds via mechanical splitting. However, depending on
the type of amyloid and its intrinsic stability, Hsp104 can also inhibit ﬁbrillization by interacting
with intermediates on the pathway of amyloid formation, see (3), (4), and (5). Nevertheless,
Hsp104 also possesses unfolding activity (6) that targets amorphous aggregates; this requires
Hsp70/40 for efﬁcient disaggregation and renaturation. The ﬁgure integrates the function of
Hsp104 modulating protein conformations into the theory of the protein folding and amyloid for-
mation by Jahn and Radford.139
270 Grimminger-Marquardt and Lashuel
Biopolymers
Alternatively, a brief treatment of amyloid ﬁbrils with pro-
teases to remove any exposed strands and loops should gen-
erate ﬁbrils without putative Hsp104 binding sites, which
would in turn be resistant to Hsp104 fragmentation.
Acceleration and Inhibition of Amyloid
Formation by Hsp104
In vitro assays showed that the ﬁbril splitting function is not
the only activity of Hsp104 on amyloid proteins. Low con-
centrations (\0.5 lg/mL) of Hsp104 have been reported to
accelerate amyloid formation in vitro in an ATP-dependent
fashion,19 which would support the templating model
(Figure 5A). However, in vitro aggregation studies also have
consistently demonstrated that at high Hsp104 concentra-
tions ([10 lg/mL) and regardless of the sequence or fold of
the aggregating protein, Hsp104 inhibits amyloid formation.
This has been rationalized by the fact that at low concentra-
tions, the prion/amyloid splitting function of Hsp104 domi-
nates, whereas at high concentration its inhibitory effects
override this activity, see case studies below. Recent studies
with amyloid-b and a-synuclein provided new insight into
how Hsp104 can block the ﬁbrillization of amyloidogenic
proteins by targeting multiple intermediates on the pathway
of amyloid formation,26,29 see Figure 5D and (3), (4), and
(5) in Figure 6. Hsp104 might inhibit amyloid formation by
binding to the monomeric protein and by stabilizing its non-
amyloidogenic native state. However, this type of interaction
would require an amyloid protein-to-Hsp104 ratio close to
1:1 in order to efﬁciently block amyloid formation. Alterna-
tively, Hsp104 could bind speciﬁcally to the polymerization
sites - or ends - of aggregation intermediates or ﬁbrils,
thereby blocking ﬁbril elongation by hindering the addition
of monomers (Figure 5D). This mechanism is consistent
with the ability of Hsp104 to block the ﬁbrillization of Ab42
at substoichiometric ratios of 1000:1 in an ATP-independent
manner.26 Current studies often lack detailed data on the
binding speciﬁcity of Hsp104 regarding amyloidogenic struc-
tures or peptide sequences. Thus, the mechanistic details of
the Hsp104 interaction with amyloid monomers, protoﬁbrils,
or ﬁbrillar seeds remain understood. It is not clear, whether
Hsp104 recognizes a ‘‘general b-amyloid fold’’ on ﬁbrillar
structures or preferentially interacts with a common
sequence or cluster of amino acids in amyloidogenic pro-
teins, as shown for Sup35-derived peptides by Glover and
coworkers.9 The lack of sequence or structural homology
among the amyloid forming proteins argues against the latter
hypothesis. Furthermore, whether Hsp104 targeting and sta-
bilization of aggregation intermediates occurs in vivo
remains unclear. The consequences of such interactions, if
present in vivo, on amyloid toxicity still need to be
elucidated. Although the protective effect of Hsp104 against
toxicity of amyloidogenic proteins in cellular and animal
models would appear to argue against this model, it is plausi-
ble that Hsp104 binding to toxic aggregation intermediates
remodels their structure and renders them nontoxic. This
may occur via a structural alteration by Hsp104 that targets
these intermediates towards proteolysis or towards other
molecular chaperones, or by simply diverting them to some
off-pathways that do not lead to amyloid formation.
Case Studies of Hsp104 Activity on Amyloid Proteins
Hsp104 exerts its speciﬁc functions on all amyloid proteins
tested so far. Its substrates comprise natural endogenous sub-
strates, such as Sup35 and Ure2 from yeast, but also exoge-
nous substrates, such as human amyloidogenic proteins, see
Table I. Since no Hsp104 ortholog was identiﬁed in humans,
the studies combining Hsp104 and human proteins might be
considered as artiﬁcial with no practical or physiologic rele-
vance. However, human amyloidogenic proteins are the best
understood model substrates for elucidating the functions of
Hsp104, and more importantly, studies involving the func-
tion of Hsp104 on these proteins provide very valuable
insight into the mechanisms of disease development, toxicity
of amyloid proteins and reversion of toxicity by molecular
chaperones.
[PSI1]/Sup35
Incubating preformed Sup35NM ﬁbrils in vitro with Hsp104
yields short ﬁbril fragments that are active in seeding the
Sup35NM amyloid formation in vitro. The ﬁbril fragmenta-
tion reaction takes place within 30–60 min and requires an
ATP regenerating system and fully functional Hsp104,19 see
Figure 5B. The observed ﬁbril fragmentation activity of
Hsp104 is independent from Hsp70/40, but Sup35 ﬁbrils that
were pre-assembled in the presence of Hsp70/40 are more
efﬁciently fragmented by Hsp104.148 However, others did not
observe ﬁbril fragmentation by Hsp104 but rather found that
full length Sup35 ﬁbrils assembled in the presence of Hsp104
possess an increased seeding capacity.20 These differences in
the Hsp104’s effects might be due to variations in sample
preparation and assay conditions. The amyloidogenic region
of the NM domain of Sup35, Sup35,5–8,12,29,32–34,41–53 served
in NMR experiments to identify the oligomeric species
of Sup355–8,12,29,32–34,41–53 preferentially interacting with
Hsp104. These hexameric/tetrameric oligomers were found
to disassemble in the presence of Hsp104.21,22 Beyond the
ﬁbril remodeling activity, Hsp104 has been shown to
accelerate Sup35 amyloid ﬁbril formation when added at
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low concentrations (0.17–0.5 lg/mL) to an on-going
ﬁbrillization experiment.19,20,24,149 At low Hsp104 concen-
trations and in the presence of ATP, the ﬁbrillization of
Sup35NM and full length Sup35 was enhanced. The
nucleation phase was dramatically shortened19,24 and/or
the ﬁnal Thioﬂavin T (ThT) ﬂuorescence values were
higher than those of the control samples.20 This enhance-
ment of ﬁbrillization supports the model of conforma-
tional alteration by Hsp104 for prion formation, see
Figure 5A. Alternatively, it has been suggested that
Hsp104 itself offers a catalytic surface for molten prion
domains to attain an amyloid nucleating state.24 However,
at high concentrations ([2.9 lg/mL), Hsp104 inhibits
amyloid formation.19–21,24 Thus, the functions of Hsp104,
ﬁbril breakage and acceleration or inhibition of amyloid
formation, depend on its concentration. Accordingly,
Hsp104 appears to have the capacity to exert multiple
effects on the formation and ampliﬁcation of Sup35 amy-
loid structures.
[URE3]/Ure2
Analogous to Sup35, it has been demonstrated that Hsp104
also catalyzes the fragmentation of mature Ure2 ﬁbrils into
smaller fragments, which are active in the seeding of amyloid
formation in vitro and also active as prion in vivo.24 Melki
and coworkers have shown that Hsp104 converts mature
Ure2 ﬁbrils into species that are less resistant to sodium
dodecyl sulfate (SDS) treatment and that are not retained in
cellulose acetate ﬁlters with 0.20-lm pore size, unlike the
ﬁbrillar Ure2 starting material.25 Furthermore, Hsp104 also
accelerates Ure2 amyloid ﬁbril formation in vitro when added
at low concentrations24,25 and inhibits Ure2 amyloid formation
at high concentrations, similar to its effect on Sup35.24
Alzheimer’s Disease/Ab42
A fusion of human amyloid-b (Ab42) peptide with the C-ter-
minal domain of Sup35 (MRF) has been used to develop a
yeast based reporter system of Alzheimer’s disease.40 The
expression of the Ab42-MRF fusion results in a [PSI1]-like
phenotype and in the formation of SDS stable oligomers of
Ab42-MRF. The phenotype and the formation of oligomers
were inﬂuenced by endogenous Hsp104 in yeast. Deletion of
the HSP104 gene decreases the amount of Ab42-MRF
oligomers and slightly suppresses the [PSI1]-like phenotype.
Hsp104 also coimmunoprecipitated with Ab42-MRF indicat-
ing an interaction.40 Interestingly, the size and structural
properties of preformed amyloid ﬁbrils or oligomers from
human Ab42 peptide are not inﬂuenced by Hsp104 in vitro,
even at higher concentrations.26 However, Hsp104 inhibits
the ﬁbrillization of monomeric and protoﬁbrillar forms of
Ab42 in a concentration-dependent, but ATP-independent,
manner. Similar to the ﬁndings for Sup35 and Ure2, Hsp104
delays the lag phase of amyloid formation. However, Ab42
seems to be more sensitive to Hsp104 and a signiﬁcant inhi-
bition can be observed at Hsp104 concentrations as low as
1 lg/mL, at a molar ratio of 1000 to 1, suggesting a preferen-
tial interaction of Hsp104 with aggregation intermediates
(e.g., oligomers, protoﬁbrils, small ﬁbrils). However, Hsp104
was found to associate with monomers but also with protoﬁ-
brils of Ab42. Since Hsp104 shows an inhibitory effect at all
stages of Ab42 aggregation, it might therefore target multiple
intermediates on the pathway to amyloid formation,26 see
Figure 5D.
Parkinson’s Disease/a-Synuclein
In vivo, overexpression of a-synuclein in yeast leads to the
formation of inclusions and causes toxicity.39 Yeast con-
tains endogenous Hsp104, interestingly, overexpression of
Hsp104 does not show any signiﬁcant effect on a-synu-
clein aggregation and toxicity.63 In the mammalian system,
the lentiviral coexpression of Hsp104 and a-synuclein in
the rat substantia nigra results in a signiﬁcant reduction
of a-synuclein aggregation and in a protection against
a-synuclein-induced loss of dopamingergic neurons in a
concentration-dependent manner.29 In vitro, Hsp104 par-
tially disassembles a-synuclein ﬁbrils in an ATP-dependent
reaction.29 Moreover, it has also been reported to possess
the capacity to remodel and disassemble the oligomeric
and protoﬁbrillar forms of a-synuclein. Unlike the obser-
vations for yeast prion proteins, Hsp104 does not acceler-
ate a-synuclein amyloid formation but inhibits its aggrega-
tion and ﬁbril formation at high concentrations of
[10 lg/mL Hsp104.29
Huntington’s disease/PolyQ
Hsp104 has been shown to be required for the aggregation of
polyglutamine (polyQ), or of huntingtin with speciﬁc polyQ
repeat, in a yeast model system of Huntington’s disease.27
However, this property is dependent on the length of the
polyQ repeats. Only long constructs[70Q form aggregates
in yeast,27,150 and the aggregation of longer polyQ constructs
is the less dependent on Hsp104.35,151 Beyond aggregation,
Meriin et al. reported that polyQ toxicity in yeast is depend-
ent on Hsp104.150 Both the deletion of HSP104 and the
expression of the dominant negative K218T/K620T double
mutant reduce polyQ toxicity.36 Overexpression of Hsp104
increases the number of small ﬂuorescent foci in yeast, i.e.,
the number of visible aggregates of polyQ.27 Other groups
have observed a resolubilization of polyQ aggregates and a
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reduced polyQ toxicity upon overexpression of Hsp104
alone152 or in conjunction with sHsps.63 Interestingly, polyQ
aggregation and toxicity depend on the presence of Rnq1
aggregates, i.e., the [RNQ1] prion state.36,37,150 Even the pro-
tective effect of Hsp104 overexpression against polyQ toxicity
was found to be dependent on the actual prion state, [PSI1]
and/or [RNQ1].36 These data indicate that Hsp104 indeed
converts amyloid structures into self-propagating prions, as
proposed by the prion splitting model, see Figure 5B; how-
ever, the huntingtin/polyQ model system also requires an
existing yeast prion state in the cell in order to be maintained
as amyloid aggregate, demonstrating that existing prion
aggregates from another protein species may serve as a tem-
plate for amyloid formation of polyQ.
In animal and cellular models of Huntington’s disease,
Hsp104 protects against polyQ toxicity and reduces its aggre-
gation. Expression of Hsp104 in C. elegans was shown to sup-
press the formation of GFP-polyQ inclusions and to reverse
the retardation in growth rates induced by polyQ aggrega-
tion.32 The expression of Hsp104 in mammalian cells,43 in
the brain of a transgenic mouse model of Huntington’s dis-
ease employing a MoPrP promoter for speciﬁc expression in
brain,33 and in striata of the brain of rats after lentiviral
injection34 protects against polyQ toxicity and reduces the
number of polyQ inclusions.
Transmissible Spongiform Encephalopathies/Prion
Protein
Hsp104 has been shown to promote the conversion of mam-
malian prion protein PrPc (cellular, soluble) into PrPres
(protease resistant). However, this process was shown to be
independent from ATP or Hsp104-ATPase-mutations.38 In a
transmissible spongiform encephalopathy (TSE) mouse
model, Hsp104 showed no enhancement or protective effects.
Hsp104 was expressed in the brain, the spinal cord, and the
cerebellum using a neuron-speciﬁc promoter. After infection
with prions by injection of brain homogenate from
ME7 mice, the recipient mice developed TSE symptoms
independent from Hsp104 expression.153 Accordingly, these
experiments suggest that Hsp104 does not cure or protect
the animals from mouse prion disease.
CONCLUSIONS
It had previously been suggested that Hsp104 recognizes
common structural features in the aggregated state of amy-
loid forming proteins. More recent evidences allow a more
differentiated understanding. Experimental data on the dif-
ferent substrates demonstrate that the ability of Hsp104 to
catalyze or inhibit prion and amyloid formation appears to
be strongly dependent on the individual stability and struc-
tural properties of the aggregates as well as on the primary
sequence and structure of the native amyloidogenic protein.
The degrees to which Hsp104 can dissociate and reverse pro-
tein aggregation are furthermore dependent on the Hsp104
concentration, on the presence of ATP, and may require the
active cooperation of other chaperones. In vitro Hsp104
appears to exert different functions on amyloid proteins and
their structures, some of which can be attributed to the clas-
sical disaggregation activity and may involve a substrate
threading mechanism. Other activities, such as the inhibition
of amyloid formation, require only Hsp104 but neither ATP
nor cochaperones. In vivo Hsp104 appears to mostly fulﬁll a
function in protein disaggregation and prion/amyloid frag-
mentation, which results in aggregate clearance and prion
propagation, respectively. Therefore, the interplay between
these different mechanisms (enhancement and suppression
of aggregation, disaggregation, and amyloid/prion fragmen-
tation) must be considered in future studies aimed at dissect-
ing the molecular mechanisms underlying Hsp104 activities
both in vivo and in vitro.
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